Progress of Nanotechnology in Diabetic Retinopathy Treatment

References

• Lauri C, Glaudemans AWJM, Signore A. Leukocyte imaging of the diabetic foot. Curr Pharm Des. 2018;24(12):1270–1276. doi:10.2174/1381612824666180227094116
   PubMedGoogle Scholar
• Lauri C, Tamminga M, Glaudemans AWJM, et al. Detection of osteomyelitis in the diabetic foot by imaging techniques: a systematic review and meta-analysis comparing MRI, white blood cell scintigraphy, and FDG-PET. Diabetes Care. 2017;40(8):1111–1120. doi:10.2337/dc17-0532
   PubMed Web of Science ®Google Scholar
• Chan KH, Lim J, Jee JE, Aw JH, Lee SS. Peptide-peptide co-assembly: a design strategy for functional detection of C-peptide, a biomarker of diabetic neuropathy. Int J Mol Sci. 2020;21(24):9671. doi:10.3390/ijms21249671
   PubMed Web of Science ®Google Scholar
• Kim SS, Song SH, Kim IJ, et al. Urinary cystatin C and tubular proteinuria predict progression of diabetic nephropathy. Diabetes Care. 2013;36(3):656–661. doi:10.2337/dc12-0849
   PubMed Web of Science ®Google Scholar
• Satirapoj B, Aramsaowapak K, Tangwonglert T, Supasyndh O. Novel tubular biomarkers predict renal progression in type 2 diabetes mellitus: a prospective cohort study. J Diabetes Res. 2016;2016:9. doi:10.1155/2016/3102962.3102962
   Google Scholar
• Mishra J, Mori K, Ma Q, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2004;15(12):3073–3082. doi:10.1097/01.ASN.0000145013.44578.45
   PubMed Web of Science ®Google Scholar
• Viau A, El Karoui K, Laouari D, et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest. 2010;120(11):4065–4076. doi:10.1172/jci42004
   PubMed Web of Science ®Google Scholar
• Yang YH, He XJ, Chen SR, Wang L, Li EM, Xu LY. Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. Endocrine. 2009;36(1):45–51. doi:10.1007/s12020-009-9187-x
   PubMedGoogle Scholar
• Satirapoj B, Wang Y, Chamberlin MP, et al. Periostin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells. Nephrol Dial Transplant. 2012;27(7):2702–2711. doi:10.1093/ndt/gfr670
   PubMed Web of Science ®Google Scholar
• Wantanasiri P, Satirapoj B, Charoenpitakchai M, Aramwit P. Periostin: a novel tissue biomarker correlates with chronicity index and renal function in lupus nephritis patients. Lupus. 2015;24(8):835–845. doi:10.1177/0961203314566634
   PubMed Web of Science ®Google Scholar
• Satirapoj B. Tubulointerstitial biomarkers for diabetic nephropathy. J Diabetes Res. 2018;2018:2852398. doi:10.1155/2018/2852398
   PubMed Web of Science ®Google Scholar
• Wilkinson CP, Ferris FL, Klein RE; Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677–1682. doi:10.1016/S0161-6420(03)00475-5
   PubMed Web of Science ®Google Scholar
• Budzinskaya MV, Petrachkov DV, Savochkina OA, Arzhukhanov DD. K voprosu o klassifikatsii diabeticheskoĭ retinopatii [On classification of diabetic retinopathy]. Vestn Oftalmol. 2019;135:272–277. Russian. doi:10.17116/oftalma2019135052272.
   PubMedGoogle Scholar
• Jiang Y. Effect of total retinal laser photocoagulation on diabetic retinopathy. Medical Equip. 2020;21:1002–2376.
   Google Scholar
• Bi SS, Ping JH, Dai X. Progress in the treatment of diabetic retinopathy with retinal laser photocoagulation. J Heze Med Coll. 2020;123:72–75.
   Google Scholar
• Kleinmann G, Hauser D, Schechtman E, Landa G, Bukelman A, Pollack A. Vitreous hemorrhage in diabetic eyes previously treated with panretinal photocoagulation. Int Ophthalmol. 2008;28(1):29–34. doi:10.1007/s10792-007-9106-1
   PubMedGoogle Scholar
• Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol. 1985;103(12):1796–1806. doi:10.1001/archopht.1985.01050120030015.
   PubMedGoogle Scholar
• Striph GG, Hart WM Jr, Olk RJ. Modified grid laser photocoagulation for diabetic macular edema. The effect on the central visual field. Ophthalmology. 1988;95(12):1673–1679. doi:10.1016/S0161-6420(88)32957-X
   PubMed Web of Science ®Google Scholar
• Sims LM, Stoessel K, Thompson JT, Hirsch J. Assessment of visual-field changes before and after focal photocoagulation for clinically significant diabetic macular edema. Ophthalmologica. 1990;200(3):133–141. doi:10.1159/000310094
   PubMed Web of Science ®Google Scholar
• Rohrschneider K, Bultmann S, Gluck R, Kruse FE, Fendrich T, Volcker HE. Scanning laser ophthalmoscope fundus perimetry before and after laser photocoagulation for clinically significant diabetic macular edema. Am J Ophthalmol. 2000;129(1):27–32. doi:10.1016/S0002-9394(99)00270-6
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kang TS, Kwak BS, Jo YJ, Kim JY. Long-term effect of panretinal photocoagulation on spectral domain optical coherence tomography measurements in diabetic retinopathy. Curr Eye Res. 2017;42(8):1169–1173. doi:10.1080/02713683.2017.1280510
   PubMed Web of Science ®Google Scholar
• Seiberth V, Alexandridis E, Feng W. Function of the diabetic retina after panretinal argon laser coagulation. Graefes Arch Clin Exp Ophthalmol. 1987;225:385–390. doi:10.1007/BF02334163
   PubMed Web of Science ®Google Scholar
• Russell PW, Sekuler R, Fetkenhour C. Visual function after pan-retinal photocoagulation: a survey. Diabetes Care. 1985;8:57–63. doi:10.2337/diacare.8.1.57
   PubMed Web of Science ®Google Scholar
• Deschler EK, Sun JK, Silva PS. Side-effects and complications of laser treatment in diabetic retinal disease. Ophthalmol. 2014;29(5–6):290–300. doi:10.3109/08820538.2014.959198
   Google Scholar
• Zhang ZH, Xu H, Mo XH. Comparison of two vitrectomy for proliferative diabetic retinopathy. Int J Ophthalmol. 2017;17(6):1174–1177.
   Google Scholar
• Brănişteanu DC, Bilha A, Moraru A. Vitrectomy surgery of diabetic retinopathy complications. Rom J Ophthalmol. 2016;60(1):31–36.
   PubMedGoogle Scholar
• Tuuminen R, Sahanne S, Haukka J, Loukovaara S. Improved outcome after primary vitrectomy in diabetic patients treated with statins. Eur J Ophthalmol. 2016;26(2):174–181. doi:10.5301/ejo.5000657
   PubMed Web of Science ®Google Scholar
• Yamada Y, Suzuma K, Ryu M, Tsuiki E, Fujikawa A, Kitaoka T. Systemic factors influence the prognosis of diabetic macular edema after pars plana vitrectomy with internal limiting membrane peeling. Curr Eye Res. 2013;38(12):1261–1265. doi:10.3109/02713683.2013.820327
   PubMed Web of Science ®Google Scholar
• Veritti D, Sarao V, Lanzetta P. A propensity-score matching comparison between 27-gauge and 25-gauge vitrectomy systems for the repair of primary rhegmatogenous retinal detachment. J Ophthalmol. 2019;2019:3120960. doi:10.1155/2019/3120960
   PubMedGoogle Scholar
• Naruse Z, Shimada H, Mori R. Surgical outcomes of 27-gauge and 25-gauge vitrectomy day surgery for proliferative diabetic retinopathy. Int Ophthalmol. 2019;39(9):1973–1980. doi:10.1007/s10792-018-1030-z
   PubMed Web of Science ®Google Scholar
• Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986. doi:10.1056/NEJM199309303291401
   PubMed Web of Science ®Google Scholar
• Lin WX, Zang J, Bao JL, Zhou LB, Zhu YD, Li Q. Compound Xueshuantong Capsule and Pancreatic Kikopeptidase in treatment of NPDR. Int J Ophthalmol. 2011;11:66–68.
   Google Scholar
• Feng XF, Mai ZL, Huang BM, Han Q, Huang Q, Mai YX. Clinical analysis of insulin combined with calcium dobesilate in the treatment of early diabetic retinopathy. Mod Hosp. 2020;217:136–139.
   Google Scholar
• Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018;19(6):1816. doi:10.3390/ijms19061816
   PubMed Web of Science ®Google Scholar
• Wroblewski JJ, Hu AY. Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as combination therapy for macular edema due to branch and central retinal vein occlusion: an Open-Label, randomized study. Ophthalmic Surg Lasers Imaging Retina. 2016;47(10):914–923. doi:10.3928/23258160-20161004-04
   PubMedGoogle Scholar
• Campochiaro PA, Khanani A, Singer M, et al. Enhanced benefit in diabetic macular edema from AKB-9778 Tie2 activation combined with vascular endothelial growth factor suppression. Ophthalmology. 2016;123(8):1722–1730. doi:10.1016/j.ophtha.2016.04.025
   PubMed Web of Science ®Google Scholar
• Jonas JB. Intravitreal triamcinolone acetonide for diabetic retinopathy. Ophthalmol. 2007;39:96–110. doi:10.1159/000098502
   Google Scholar
• Phillips K, Katz HR. A comparison of the efficacy of dexamethasone and loteprednol on endotoxin-induced uveitis in rodents following topical ocular administration. Invest Ophthalmol Vis Sci. 2005;46:983.
   Google Scholar
• Qian Y, Wenting C, Huizi J, Donghui Y, Tianyi SH, Jing Y. Application and safety of polyethyleneimine-modified sodium fluorescein nanoparticles in fundus fluorescein angiography. New Dev Ophthalmol. 2020;293:10–15.
   Google Scholar
• Vadanasundari V, Huang L, Zhang M, et al. Vanadium core–shell nanorods inspect metabolic changes of diabetic retinopathy. Adv Funct Mater. 2020.
   Google Scholar
• Gao X, Li Y, Wang H, Li C, Ding J. Inhibition of HIF-1α decreases expression of pro-inflammatory IL-6 and TNF-α in diabetic retinopathy. Acta Ophthalmol. 2017;95(8):746–750. doi:10.1111/aos.13096
   Google Scholar
• Gong Q, Xie J, Li Y, Liu Y, Su G. Enhanced ROBO4 is mediated by up-regulation of HIF-1α/SP1 or reduction in miR-125b-5p/miR-146a-5p in diabetic retinopathy. J Cell Mol Med. 2019;23(7):4723–4737. doi:10.1111/jcmm.14369
   PubMedGoogle Scholar
• Iwase T, Fu J, Yoshida T, et al. Sustained delivery of a HIF-1 antagonist for ocular neovascularization. J Control Release. 2013;172(3):625–633. doi:10.1016/j.jconrel.2013.10.008
   PubMed Web of Science ®Google Scholar
• Badr GA, Tang J, Ismail-Beigi F, Kern TS. Diabetes downregulates GLUT1 expression in the retina and its microvessels but not in the cerebral cortex or its microvessels. Diabetes. 2000;49(6):1016–1021. doi:10.2337/diabetes.49.6.1016
   PubMed Web of Science ®Google Scholar
• Ulas M, Orhan C, Tuzcu M, et al. Anti-diabetic potential of chromium histidinate in diabetic retinopathy rats. BMC Complement Altern Med. 2015;15:16. doi:10.1186/s12906-015-0537-3
   PubMed Web of Science ®Google Scholar
• Gao X, Han B. Preparation and pharmacodynamics of nanoparticles for diabetic retinopathy. Jilin University; 2020.
   Google Scholar
• Hao H, Cai J, Jiang L. Effect of nanoparticle-mediated triamcinolone acetonide delivery on the treatment of diabetic rat retinopathy. Pract Drugs Clin. 2019;4:359–363.
   Google Scholar
• Lu Y, Zhou N, Huang X, et al. Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats. Int J Ophthalmol. 2014;7(1):1–7. doi:10.3980/j.issn.2222-3959.2014.01.01
   PubMed Web of Science ®Google Scholar
• Araújo J, Garcia ML, Mallandrich M, Souto EB, Calpena AC. Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies. Nanomedicine. 2012;8(6):1034–1041. doi:10.1016/j.nano.2011.10.015
   PubMed Web of Science ®Google Scholar
• Araújo J, Nikolic S, Egea MA, Souto EB, Garcia ML. Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf B Biointerfaces. 2011;88(1):150–157. doi:10.1016/j.colsurfb.2011.06.025
   PubMed Web of Science ®Google Scholar
• Gonzalez-Mira E, Egea MA, Souto EB, Calpena AC, García ML. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology. 2011;22(4):045101. doi:10.1088/0957-4484/22/4/045101
   PubMed Web of Science ®Google Scholar
• Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf B Biointerfaces. 2010;81(2):412–421. doi:10.1016/j.colsurfb.2010.07.029
   PubMed Web of Science ®Google Scholar
• Souto EB, Doktorovova S, Gonzalez-Mira E, Egea MA, Garcia ML. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs. Curr Eye Res. 2010;35(7):537–552. doi:10.3109/02713681003760168
   PubMed Web of Science ®Google Scholar
• Araújo J, Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int J Pharm. 2010;393(1–2):167–175. doi:10.1016/j.ijpharm.2010.03.034
   PubMed Web of Science ®Google Scholar
• Zhu HM, Huang PC, Zhao TT, et al. In vitro genotoxicity of silver nanoparticles and titanium dioxide nanoparticles. Hereditary. 2020;42:56–64.
   Google Scholar
• Piao MY, Zhao JW. Research progress of magnetic iron oxide nanoparticles in biomedical application. Huaihai Med. 2020;38:110–113.
   Google Scholar
• Xu LS, Li WD, Shi Q. Synthesis of mulberry leaf extract mediated gold nanoparticles and their ameliorative effect on Aluminium intoxicated and diabetic retinopathy in rats during perinatal life. J Photochem Photobiol B. 2019;196:111502. doi:10.1016/j.jphotobiol.2019.04.011
   PubMed Web of Science ®Google Scholar
• Amadio M, Pascale A, Cupri S, et al. Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat. Pharmacol Res. 2016;111:713–720. doi:10.1016/j.phrs.2016.07.042
   PubMed Web of Science ®Google Scholar
• Zamani M, Shirinzadeh A, Aghajanzadeh M, Andalib S, Danafar H. In vivo study of mPEG-PCL as a nanocarriers for anti-inflammatory drug delivery of simvastatin. Pharm Dev Technol. 2019;24(6):663–670. doi:10.1080/10837450.2018.1556689
   PubMed Web of Science ®Google Scholar
• Amato R, Giannaccini M, Dal Monte M, et al. Association of the somatostatin analog octreotide with magnetic nanoparticles for intraocular delivery: a possible approach for the treatment of diabetic retinopathy. Front Bioeng Biotechnol. 2020;8:144. doi:10.3389/fbioe.2020.00144
   PubMed Web of Science ®Google Scholar
• Shoval A, Markus A, Zhou Z, et al. Anti-VEGF-aptamer modified C-Dots-A hybrid nanocomposite for topical treatment of ocular vascular disorders. Small. 2019;15(40):e1902776. doi:10.1002/smll.201902776
   PubMedGoogle Scholar
• Kador PF, Wyman M, Oates PJ. Aldose reductase, ocular diabetic complications and the development of topical Kinostat. Prog Retin Eye Res. 2016;54:1–29. doi:10.1016/j.preteyeres.2016.04.006
   PubMed Web of Science ®Google Scholar
• Liu Z, Yu N, Holz FG, Yang F, Stanzel BV. Enhancement of retinal pigment epithelial culture characteristics and subretinal space tolerance of scaffolds with 200 nm fiber topography. Biomaterials. 2014;35(9):2837–2850. doi:10.1016/j.biomaterials.2013.12.069
   PubMed Web of Science ®Google Scholar
• Chang YC, Chen MH, Liao SY, et al. Multichanneled nerve guidance conduit with spatial gradients of neurotrophic factors and oriented nanotopography for repairing the peripheral nervous system. ACS Appl Mater Interfaces. 2017;9(43):37623–37636. doi:10.1021/acsami.7b12567
   PubMed Web of Science ®Google Scholar
• Yan L, Zhao B, Liu X, et al. Aligned nanofibers from polypyrrole/graphene as electrodes for regeneration of optic nerve via electrical stimulation. ACS Appl Mater Interfaces. 2016;8(11):6834–6840. doi:10.1021/acsami.5b12843
   PubMed Web of Science ®Google Scholar
• Jing Y, Moore LR, Williams PS, et al. Blood progenitor cell separation from clinical leukapheresis product by magnetic nanoparticle binding and magnetophoresis. Biotechnol Bioeng. 2007;96(6):1139–1154. doi:10.1002/bit.21202
   PubMedGoogle Scholar
• Nadri S, Kazemi B, Eeslaminejad MB, et al. High yield of cells committed to the photoreceptor-like cells from conjunctiva mesenchymal stem cells on nanofibrous scaffolds. Mol Biol Rep. 2013;40:3883–3890. doi:10.1007/s11033-012-2360-y
   PubMed Web of Science ®Google Scholar
• Ebrahimi-Barough S, Hoveizi E, Javidan N, et al. Investigating the neuroglial differentiation effect of neuroblastoma conditioned medium in human endometrial stem cells cultured on 3D nanofibrous scaffold. J Biomed Mater Res A. 2015;103:2621–2627. doi:10.1002/jbm.a.35397
   PubMed Web of Science ®Google Scholar
• Froelich K, Pueschel RC, Birner M, et al. Optimization of fibrinogen isolation for manufacturing autologous fibrin glue for use as scaffold in tissue engineering. Artif Cells Blood Subst Biotech. 2010;38:143–149. doi:10.3109/10731191003680748
   PubMed Web of Science ®Google Scholar
• Soleimannejad M, Ebrahimi-Barough S, Soleimani M, et al. Fibrin gel as a scaffold for photoreceptor cells differentiation from conjunctiva mesenchymal stem cells in retina tissue engineering. Artif Cells Nanomed Biotechnol. 2018;46(4):805–814. doi:10.1080/21691401.2017.1345922
   PubMed Web of Science ®Google Scholar
• Li S, Huang L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther. 1997;4(9):891–900. doi:10.1038/sj.gt.3300482
   PubMed Web of Science ®Google Scholar
• Li S, Rizzo MA, Bhattacharya S, Huang L. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther. 1998;5(7):930–937. doi:10.1038/sj.gt.3300683
   PubMed Web of Science ®Google Scholar
• Long J, Kim H, Kim D, Lee JB, Kim DH. A biomaterial approach to cell reprogramming and differentiation. J Mater Chem B. 2017;5(13):2375–2379. doi:10.1039/C6TB03130G
   PubMedGoogle Scholar
• Cao B, Qiu P, Mao C. Mesoporous iron oxide nanoparticles prepared by polyacrylic acid etching and their application in gene delivery to mesenchymal stem cells. Microsc Res Tech. 2013;76(9):936–941. doi:10.1002/jemt.22251
   PubMedGoogle Scholar
• Kutsuzawa K, Chowdhury EH, Nagaoka M, Maruyama K, Akiyama Y, Akaike T. Surface functionalization of inorganic nano-crystals with fibronectin and E-cadherin chimera synergistically accelerates trans-gene delivery into embryonic stem cells. Biochem Biophys Res Commun. 2006;350(3):514–520. doi:10.1016/j.bbrc.2006.09.081
   PubMedGoogle Scholar
• Fangueiro JF, Andreani T, Egea MA, et al. Design of cationic lipid nanoparticles for ocular delivery: development, characterization and cytotoxicity. Int J Pharm. 2014;461(1–2):64–73. doi:10.1016/j.ijpharm.2013.11.025
   PubMed Web of Science ®Google Scholar
• Kompella UB, Amrite AC, Pacha Ravi R, Durazo SA. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res. 2013;36:172–198. doi:10.1016/j.preteyeres.2013.04.001
   PubMed Web of Science ®Google Scholar
• Yang J, Cai L, Zhang S, Zhu X, Zhou P, Lu Y. Silica-based cerium (III) chloride nanoparticles prevent the fructose-induced glycation of α-crystallin and H₂O₂-induced oxidative stress in human lens epithelial cells. Arch Pharm Res. 2014;37(3):404–411. doi:10.1007/s12272-013-0195-2
   PubMedGoogle Scholar
• Jo DH, Kim JH, Yu YS, Lee TG, Kim JH. Antiangiogenic effect of silicate nanoparticle on retinal neovascularization induced by vascular endothelial growth factor. Nanomedicine. 2012;8(5):784–791. doi:10.1016/j.nano.2011.09.003
   PubMedGoogle Scholar
• Gurunathan S, Lee KJ, Kalishwaralal K, Sheikpranbabu S, Vaidyanathan R, Eom SH. Antiangiogenic properties of silver nanoparticles. Biomaterials. 2009;30(31):6341–6350. doi:10.1016/j.biomaterials.2009.08.008
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim MH, Jo DH, Yu YS, Lee TG, Kim JH. The inhibition of retinal neovascularization by gold nanoparticles via suppression of VEGFR-2 activation. Biomaterials. 2011;32(7):1865–1871. doi:10.1016/j.biomaterials.2010.11.030
   PubMed Web of Science ®Google Scholar
• Varshochian R, Jeddi-Tehrani M, Mahmoudi AR, et al. The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. Eur J Pharm Sci. 2013;50(3–4):341–352. doi:10.1016/j.ejps.2013.07.014
   PubMed Web of Science ®Google Scholar
• Bysell H, Månsson R, Hansson P, Malmsten M. Microgels and microcapsules in peptide and protein drug delivery. Adv Drug Deliv Rev. 2011;63(13):1172–1185. doi:10.1016/j.addr.2011.08.005
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505–522. doi:10.1016/j.jconrel.2012.01.043
   PubMed Web of Science ®Google Scholar
• Pusparajah P, Lee LH, Abdul Kadir K. Molecular Markers of Diabetic Retinopathy: Potential Screening Tool of the Future? Front Physiol. 2016;7:200. doi:10.3389/fphys.2016.00200
   PubMedGoogle Scholar